| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
Cancer and Polio Research Fund Laboratories, School of Biological Sciences [P. S. R., A. P-H., M. E-T., S. d. S. R., R. B.], Cancer Tissue Bank Research Centre [P. S. R.], Department of Pathology [R. H.], and Department of Public Health [C. R. W.], University of Liverpool, and Breast Unit, Royal Liverpool University Hospital [J. H. R. W.], Liverpool, L69 3BX, United Kingdom
The adhesive glycophosphoprotein (OPN) is capable of inducing metastasis in rodent models ofbreast cancer. We now show that a monoclonal antibody to rat OPN recognizes specifically human OPN using Western blotting techniques andused it to assess the prognostic significance of OPN in primary tumors of a group of 333 patients treated between 1976 and 1982 for operable stage I and stage II breast cancer. The antibody stains immunocytochemically normal breast tissue weakly but pregnant/lactating tissue and 66% of the carcinomas strongly, leaving the remaining 34% as negatively stained. In addition to the carcinoma cells, some host reactive stromal cells, macrophages, lymphocytes, and blood vessels are also stained, but these have been excluded in the following analyses. There is a significant association of staining of carcinomas for OPN with some tumor variables reported previously to be associated with patient outcome: high histological grade (P = 0.024), staining for c-erbB-3 (P < 0.001), p53 (P = 0.014), pS2 (P = 0.025), and borderline significance for progesterone receptor (P = 0.089). The association of staining for OPN with survival times of the patients has been evaluated using life tables over 14–20 years of follow-up (mean 16 years) and analyzed using generalized Wilcoxon statistics. Of the patients who have been classified as OPN-negative, 94% are alive, but only 26% of those classified as OPN-positive are alive after 19 years of follow-up. This association is highly significant (P < 0.0001); the former have a median survival of >228 months and the latter 68 months. When the patients are divided into separate classes based on the percentage of carcinoma cells staining for OPN, the five classes show a progressive decrease in survival with increasing percentage of stained carcinoma cells, and this association is also highly significant (P < 0.0001). Other tumor variables that show a significant association with patient survival times in this group of patients include nodal status, tumor size, histological grade, staining for c-erbB-2, estrogen receptor 
, or p53. Analysis of the association of patients with carcinomas staining for OPN and their survival in subgroups defined by these tumor variables shows that positive staining for OPN in each subgroup is associated with poorer survival. There is little difference in patient survival times in the OPN-negative group of patients with or without any of the other tumor variables examined. Multivariate regression analysis for 202 patients shows that staining for OPN is most highly correlated with patients’ deaths (P < 0.0001), but involved lymph nodes (P = 0.0007), fixed tumors (P = 0.0008), and staining for estrogen receptor (P = 0.008) are also significant independent prognostic variables with that for c-erbB-2 being of borderline significance (P = 0.060). These results suggest that in this group of patients, the presence of the metastasis-associated protein OPN is tightly correlated with patient demise.
This article has been cited by other articles:
|
|
 |
|
  D. J. Caruso, A. J.K. Carmack, V. B. Lokeshwar, R. C. Duncan, M. S. Soloway, and B. L. Lokeshwar Osteopontin and Interleukin-8 Expression is Independently Associated with Prostate Cancer Recurrence Clin. Cancer Res., July 1, 2008; 14(13): 4111 - 4118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Mason, S. McFarlane, P. G. Johnston, P. Crowe, P. J. Erwin, M. M. Domostoj, F. C. Campbell, S. Manaviazar, K. J. Hale, and M. El-Tanani Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation Mol. Cancer Ther., March 1, 2008; 7(3): 548 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suzuki, E. Mose, C. Galloy, and D. Tarin Osteopontin Gene Expression Determines Spontaneous Metastatic Performance of Orthotopic Human Breast Cancer Xenografts Am. J. Pathol., August 1, 2007; 171(2): 682 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cheng, D.-H. Huo, D.-M. Kuang, J. Yang, L. Zheng, and S.-M. Zhuang Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumor Cells Cancer Res., June 1, 2007; 67(11): 5141 - 5147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. El-Tanani, F. C. Campbell, P. Crowe, P. Erwin, D. P. Harkin, P. Pharoah, B. Ponder, and P. S. Rudland BRCA1 Suppresses Osteopontin-mediated Breast Cancer J. Biol. Chem., September 8, 2006; 281(36): 26587 - 26601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Allan, R. George, S. A. Vantyghem, M. W. Lee, N. C. Hodgson, C. J. Engel, R. L. Holliday, D. P. Girvan, L. A. Scott, C. O. Postenka, et al. Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer Am. J. Pathol., July 1, 2006; 169(1): 233 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H.C. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin, A. Tomiak, F. Perera, T. A. Vandenberg, and A. F. Chambers Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3337 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Burkhardt, E Mayordomo, K-J Winzer, F Fritzsche, T Gansukh, S Pahl, W Weichert, C Denkert, H Guski, M Dietel, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer J. Clin. Pathol., April 1, 2006; 59(4): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Fritzsche, E. Dahl, S. Pahl, M. Burkhardt, J. Luo, E. Mayordomo, T. Gansukh, A. Dankof, R. Knuechel, C. Denkert, et al. Prognostic Relevance of AGR2 Expression in Breast Cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1728 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le, E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers Clin. Cancer Res., March 1, 2006; 12(5): 1507 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. de Silva Rudland, L. Martin, C. Roshanlall, J. Winstanley, S. Leinster, A. Platt-Higgins, J. Carroll, C. West, R. Barraclough, and P. Rudland Association of S100A4 and Osteopontin with Specific Prognostic Factors and Survival of Patients with Minimally Invasive Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1192 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, Y. Hashimoto, E. Tanaka, T. Kan, S. Tsunoda, F. Sato, M. Higashiyama, T. Okumura, and Y. Shimada An Inducible Short-Hairpin RNA Vector against Osteopontin Reduces Metastatic Potential of Human Esophageal Squamous Cell Carcinoma In vitro and In vivo Clin. Cancer Res., February 15, 2006; 12(4): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wang, A. Platt-Higgins, J. Carroll, S. de Silva Rudland, J. Winstanley, R. Barraclough, and P. S. Rudland Induction of Metastasis by S100P in a Rat Mammary Model and Its Association with Poor Survival of Breast Cancer Patients Cancer Res., January 15, 2006; 66(2): 1199 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Hu, D. Lin, J. Yuan, T. Xiao, H. Zhang, W. Sun, N. Han, Y. Ma, X. Di, M. Gao, et al. Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4646 - 4652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, P. S. Rudland, D. R. Sibson, A. Platt-Higgins, and R. Barraclough Human Homologue of Cement Gland Protein, a Novel Metastasis Inducer Associated with Breast Carcinomas Cancer Res., May 1, 2005; 65(9): 3796 - 3805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Martinetti, E Bajetta, L Ferrari, N Zilembo, E Seregni, M Del Vecchio, R Longarini, I La Torre, L Toffolatti, D Paleari, et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole Endocr. Relat. Cancer, December 1, 2004; 11(4): 771 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. El-Tanani, A. Platt-Higgins, P. S. Rudland, and F. C. Campbell Ets Gene PEA3 Cooperates with {beta}-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin Transcription J. Biol. Chem., May 14, 2004; 279(20): 20794 - 20806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
S. Schneider, J. Yochim, J. Brabender, K. Uchida, K. D. Danenberg, R. Metzger, P. M. Schneider, D. Salonga, A. H. Holscher, and P. V. Danenberg Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1588 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Korkola, S. DeVries, J. Fridlyand, E. S. Hwang, A. L. H. Estep, Y.-Y. Chen, K. L. Chew, S. H. Dairkee, R. M. Jensen, and F. M. Waldman Differentiation of Lobular versus Ductal Breast Carcinomas by Expression Microarray Analysis Cancer Res., November 1, 2003; 63(21): 7167 - 7175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Chang, M. Cao, and P. Hicks Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells Carcinogenesis, November 1, 2003; 24(11): 1749 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kristiansen, K.-J. Winzer, E. Mayordomo, J. Bellach, K. Schluns, C. Denkert, E. Dahl, C. Pilarsky, P. Altevogt, H. Guski, et al. CD24 Expression Is a New Prognostic Marker in Breast Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4906 - 4913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhang, B. He, and G. F. Weber Growth Factor Signaling Induces Metastasis Genes in Transformed Cells: Molecular Connection between Akt Kinase and Osteopontin in Breast Cancer Mol. Cell. Biol., September 15, 2003; 23(18): 6507 - 6519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Furger, A. L. Allan, S. M. Wilson, C. Hota, S. A. Vantyghem, C. O. Postenka, W. Al-Katib, A. F. Chambers, and A. B. Tuck {beta}3 Integrin Expression Increases Breast Carcinoma Cell Responsiveness to the Malignancy-Enhancing Effects of Osteopontin Mol. Cancer Res., September 1, 2003; 1(11): 810 - 819. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
